NCT06689839View on ClinicalTrials.gov

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

NANot yet recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Aortic Stenosis Treated With TAVIAortic Diseases
Interventions
DEVICE

F2 Filter and Delivery System

Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure

PROCEDURE

Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device

Trial Locations (5)

10032

Cumc/Nyph, New York

43214

Ohio Health Research Institute (aka Riverside Methodist Hospital), Columbus

46260

St. Vincent Hospital, Indianapolis

48202

Henry Ford Hospital, Detroit

64111

St. Lukes Hospital Of Kansas City, Kansas City

Sponsors

Collaborators (1)

Avania
All Listed Sponsors
collaborator

Avania

INDUSTRY

collaborator

Insight Medical Consulting

UNKNOWN

lead

EnCompass Technologies, Inc.

INDUSTRY

NCT06689839 - Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | Biotech Hunter | Biotech Hunter